Company Plans to Initiate First-in-Human Phase 1/2 Trial in 1H 2026, Anchored by a Leading U.S. Academic Medical ...
In vitro findings reveal Telomir-1’s dual action: targeting DNA methylation switches and cutting into the Wnt “fuel line” that drives cancer growth. MIAMI, FLORIDA / ACCESS Newswire / August 28, 2025 ...
Dr. Jennifer Amengual explains how epigenetic therapies treat lymphomas by changing gene expression rather than killing dividing cells like chemotherapy. Epigenetic therapies are offering a more ...
Cancer incidence rises sharply with age, yet the biological mechanisms that make older patients more vulnerable to treatment failure remain poorly ...
Calgary, Alberta and Amsterdam, Netherlands--(Newsfile Corp. - October 27, 2025) - Zenith Epigenetics Ltd. ("Zenith" or the "Company") is pleased to announce that the U.S. Food and Drug Administration ...
Emerging biotechnology company aims to unlock targeting of disease-specific epigenetic protein interfaces to develop next-generation therapies for pediatric cancers TippingPoint Biosciences today ...
During the process of metastasis, tumor cells inevitably encounter the stimulation of various oxidative stressors, resulting in the fluctuation of intracellular reactive oxygen species (ROS) levels.
That is because scientists keen to achieve more precise control over an organism’s genetics are experimenting with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results